Institute for Biomedical Research and Innovation, National Research Council, Contrada Burga, Piano Lago, 87050 Mangone (CS) and Via Paolo Gaifami 18, 95126 Catania, Italy.
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, 87036 Cosenza, Italy.
Int J Mol Sci. 2019 Jul 30;20(15):3717. doi: 10.3390/ijms20153717.
Epilepsy refers to a common chronic neurological disorder that affects all age groups. Unfortunately, antiepileptic drugs are ineffective in about one-third of patients. The complex interindividual variability influences the response to drug treatment rendering the therapeutic failure one of the most relevant problems in clinical practice also for increased hospitalizations and healthcare costs. Recent advances in the genetics and neurobiology of epilepsies are laying the groundwork for a new personalized medicine, focused on the reversal or avoidance of the pathophysiological effects of specific gene mutations. This could lead to a significant improvement in the efficacy and safety of treatments for epilepsy, targeting the biological mechanisms responsible for epilepsy in each individual. In this review article, we focus on the mechanism of the epilepsy pharmacoresistance and highlight the use of a systems biology approach for personalized medicine in refractory epilepsy.
癫痫是一种常见的慢性神经系统疾病，可影响所有年龄段的人群。不幸的是，大约三分之一的患者对抗癫痫药物没有反应。复杂的个体间变异性会影响药物治疗的反应，使治疗失败成为临床实践中最相关的问题之一，还会导致住院和医疗保健费用增加。癫痫遗传学和神经生物学的最新进展为新的个性化医学奠定了基础，重点是逆转或避免特定基因突变的病理生理影响。这可能会显著提高针对每个个体癫痫生物学机制的治疗效果和安全性。在这篇综述文章中，我们重点关注癫痫药物耐药性的机制，并强调在难治性癫痫中使用系统生物学方法进行个性化医学。
